Granted Patent B2

US 12,576,151 · App. 18/246,656 · Granted Mar 17, 2026

Inventor: Jason Gehrke (Cambridge, MA)

Assignee: Beam Therapeutics Inc.

A61K40/4224A61K40/11A61K40/22A61K40/31A61K40/421A61P35/02C07K14/7051C07K16/2806C12N5/0636C12N5/0646C12N15/907A61K2239/28A61K2239/48C07K2317/622

Abstract

Claims (17)

1 . A chimeric antigen receptor (CAR) comprising:

an anti-CD2 binding domain comprising an amino acid sequence selected from the group consisting of:

SEQ ID NO: 383; SEQ ID NO: 385; SEQ ID NO: 386; and SEQ ID NO: 387;

a transmembrane domain;

a CD2 signaling domain having at least 85% identity to an amino acid sequence selected from the group consisting of:

SEQ ID NO: 370; SEQ ID NO: 371; SEQ ID NO: 372; SEQ ID NO: 373; SEQ ID NO: 374; SEQ ID NO: 375; SEQ ID NO: 376; SEQ ID NO: 377; SEQ ID NO: 378; SEQ ID NO: 379; and SEQ ID NO: 380;

a leader peptide sequence; and

one or more additional signaling domains, the one or more additional signaling domains selected from a CD3ζ signaling domain, a CD28 signaling domain, and a CD137 (4-1BB) signaling domain.

2 . The CAR of claim 1 , wherein the transmembrane domain is a CD8a transmembrane.

3 . The CAR of claim 1 , wherein the leader peptide sequence has at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identity to the amino acid sequence set forth in SEQ ID NO: 753.

4 . The CAR of claim 1 , wherein the CD2 signaling domain is at least 90% or 95% identical to the sequence of the CD2 signaling domain selected from the group consisting of SEQ ID NO: 370; SEQ ID NO: 371; SEQ ID NO: 372; SEQ ID NO: 373; SEQ ID NO: 374; SEQ ID NO: 375; SEQ ID NO: 376; SEQ ID NO: 377; SEQ ID NO: 378; SEQ ID NO: 379; and SEQ ID NO: 380.

5 . A chimeric antigen receptor (CAR), wherein the CAR comprises any one of the following amino acid sequences:

SEQ ID NO: 755; SEQ ID NO: 757; SEQ ID NO: 758; SEQ ID NO: 759; SEQ ID NO: 762; SEQ ID NO: 764; SEQ ID NO: 765; and SEQ ID NO: 766.

6 . A nucleic acid encoding the chimeric antigen receptor of claim 1 .

7 . An anti-CD2 binding domain comprising an amino acid sequence selected from the group consisting of:

SEQ ID NO: 383; SEQ ID NO: 385; SEQ ID NO: 386; and SEQ ID NO: 387.

8 . A nucleic acid encoding the anti-CD2 binding domain of claim 7 .

Assignments (4)

Continuity (2)

References Cited (400)